Trevi Therapeutics, Inc. is a late-stage clinical development company focused on developing Nalbuphine ER for chronic pruritus (itch).

Trevi Therapeutics Selected to Exhibit Poster at American Society of Nephrology Kidney Week 2014
Title of Abstract: Exploring Clinical and Pharmacological Effects of Nalbuphine HCl Oral Tablets in Hemodialysis Subjects with Pruritus
Trevi Therapeutics Announces Second Closing of $26 Million Series B Financing for Development of Nalbuphine ER
Uremic pruritus trial enrolling ahead of schedule and Company preparing to initiate trial in prurigo nodularis